About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Pediatric Neurology Research group is mainly involved in the study of genetic diseases of the developing nervous system. The main emphasis is on paroxysmal neurological disorders and neuromuscular disorders. A common theme across the different projects, besides the identification of the molecular basis of several of these rare disorders, is the investigation of molecules involved in their pathophysiological mechanisms and the effective translation of these findings into the fields of molecular diagnosis, genetic counselling and newly developed gene or drug therapies.
PMID: 34087982 Journal: Stem Cell Research Year: 2021 Reference: Stem Cell Res. 2021 May;53:102338. doi: 10.1016/j.scr.2021.102338. Epub 2021 Apr 15. Impact factor: 2.02 Publication type: Paper in international publication Authors: Erceg, Slaven, Espinos, Carmen, Perez-Duenas, Belen, Sanchez-Alcazar, Jose Antonio, Villalon-Garcia, Irene, Darling, Alejandra, Machuca, Candela, Correa-Vela, Marta, Garcia-Navas, Deyanira et al. DOI: 10.1016/j.scr.2021.102338
PMID: 33886091 Journal: MOLECULAR NEUROBIOLOGY Year: 2021 Reference: Mol Neurobiol. 2021 Aug;58(8):3938-3952. doi: 10.1007/s12035-021-02391-0. Epub 2021 Apr 22. Impact factor: 5.59 Publication type: Review in international publication Authors: Cazurro-Gutierrez, Ana, Marce-Grau, Anna, Correa-Vela, Marta, Salazar, Ainara, Vanegas, Maria I, Macaya, Alfons, Bayes, Alex, Perez-Duenas, Belen et al. DOI: 10.1007/s12035-021-02391-0
PMID: 33801522 Journal: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Year: 2021 Reference: Int J Mol Sci. 2021 Mar 2;22(5). pii: ijms22052505. doi: 10.3390/ijms22052505. Impact factor: 5.924 Publication type: Paper in international publication Authors: Sancho, Paula, Andres-Borderia, Amparo, Gorria-Redondo, Nerea, Llano, Katia, Martinez-Rubio, Dolores, Yoldi-Petri, Maria Eugenia, Blumkin, Luba, Rodriguez de la Fuente, Pablo, Gil-Ortiz, Fernando, Fernandez-Murga, Leonor et al. DOI: 10.3390/ijms22052505
PMID: 33349592 Journal: EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY Year: 2021 Reference: Eur J Paediatr Neurol. 2021 Jan;30:144-154. doi: 10.1016/j.ejpn.2020.10.004. Epub 2020 Oct 20. Impact factor: 3.14 Publication type: Paper in international publication Authors: Riant, Florence, Gur-Hartman, Tamar, Berkowitz, Oren, Yosovich, Keren, Roubertie, Agathe, Zanni, Ginevra, Macaya, Alfons, Heimer, Gali, Duenas, Belen Perez, Sival, Deborah A et al. DOI: 10.1016/j.ejpn.2020.10.004
PMID: 30799092 Journal: EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY Year: 2019 Reference: Eur J Paediatr Neurol. 2019 May;23(3):427-437. doi: 10.1016/j.ejpn.2019.02.001. Epub 2019 Feb 14. Impact factor: 2.496 Publication type: Paper in international publication Authors: Fryssira, Helen, Zouvelou, Vasiliki, Yubero, Delia, Apostolakopoulou, Loukia, Kokkinou, Eleftheria, Bilanakis, Manolis, Dalivigka, Zoi, Nikas, Ioannis, Kollia, Elissavet, Perez-Duenas, Belen et al. DOI: 10.1016/j.ejpn.2019.02.001
PMID: 30349988 Journal: JIMD reports Year: 2019 Reference: JIMD Rep. 2019;45:65-69. doi: 10.1007/8904_2018_138. Epub 2018 Oct 23. Impact factor: 0 Publication type: Paper in international publication Authors: van Kuilenburg, Andre B P, Meijer, Judith, Meinsma, Rutger, Perez-Duenas, Belen, Alders, Marielle, Bhuiyan, Zahurul A, Artuch, Rafael, Hennekam, Raoul C M et al. DOI: 10.1007/8904_2018_138
PMID: 30642748 Journal: MOLECULAR GENETICS AND METABOLISM Year: 2019 Reference: Mol Genet Metab. 2019 Mar;126(3):250-258. doi: 10.1016/j.ymgme.2019.01.001. Epub 2019 Jan 5. Impact factor: 3.61 Publication type: Paper in international publication Authors: Baide-Mairena, Heidy, Gaudo, Paula, Marti-Sanchez, Laura, Emperador, Sonia, Sanchez-Montanez, Angel, Alonso-Luengo, Olga, Correa, Marta, Grau, Anna Marce, Artuch, Rafael, Vazquez, Elida et al. DOI: 10.1016/j.ymgme.2019.01.001
PMID: 30642807 Journal: PARKINSONISM & RELATED DISORDERS Year: 2019 Reference: Parkinsonism Relat Disord. 2019 Apr;61:7-9. doi: 10.1016/j.parkreldis.2019.01.004. Epub 2019 Jan 8. Impact factor: 4.36 Publication type: Letter or abstract Authors: Marce-Grau, Anna, Correa, Marta, Vanegas, Maria Isabel, Munoz-Ruiz, Teresa, Ferrer-Aparicio, Silvia, Perez-Duenas, Belen, Macaya, Alfons, Baide, Heidy et al. DOI: 10.1016/j.parkreldis.2019.01.004
The ClinPrior algorithm achieved a positive diagnosis rate of 70% in two minority diseases of neurodegenerative origin, which represents double the number of cases that are diagnosed with current tools.
Over the course of two days, experts presented the latest advances in vectors, different gene modification techniques and their transfer to clinical practice.
El 20% dels pacients en els quals s’havia trobat alguna predisposició genètica van ser diagnosticats amb algun tipus de tumor i van poder iniciar el tractament de manera precoç.
